Is it safe?
Can JAZZ take a bad year?
Jazz Pharmaceuticals plc carries $3.51B of net debt at 11.3× EBITDA: a heavy load to carry through a bad year.
$3.51B
Net debt · as at Q1 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 11.3×
Net debt / EBITDA · 3.78× a year ago · the load is going up
- Debt / equity
- 1.18×
Debt / equity
- Annualised volatility
- 36%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ1 2026
- $5.35B
- Cash and short-term investments
- $1.84B
- Net debt
- $3.51B
- EBITDA, trailing twelve months
- $311M
- Operating profit, trailing twelve months
- −$38M
- Debt / equity
- 1.18×
- Total debt / EBITDA
- 17.2×
- Annualised volatilitytwo years of daily moves
- 36%
- Worst drawdown on file
- −52%
- Below its 52-week high
- −4.7%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.